Regina W. Wang

发表

Assessment of the CYP3A‐Mediated Drug Interaction Potential of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Volunteers

A. Bergman, J. Wagner, R. Krishna, 2009, Journal of clinical pharmacology.

Pharmacokinetics and Interactions of a Novel CCR5 Receptor Antagonist with Ritonavir in Rats and Monkeys: Role of CYP3A and P-glycoprotein

T. Baillie, Jiunn H. Lin, Sanjeev Kumar, 2002 .

Determination of phase I metabolic enzyme activities in liver microsomes of Mrp2 deficient TR- and EHBR rats.

D. C. Evans, D. Newton, Regina W. Wang, 2005, Life sciences.

INHIBITORY ANTI-CYP 3 A 4 PEPTIDE ANTIBODY : MAPPING OF INHIBITORY EPITOPE AND SPECIFICITY TOWARD OTHER CYP 3 A ISOFORMS

T. Rushmore, M. Shou, D. Newton, 1999 .

Substrate Specificity, Gene Structure, and Tissue-specific Distribution of Multiple Human 3α-Hydroxysteroid Dehydrogenases (*)

K. Cheng, M. Khanna, Regina W. Wang, 1995, The Journal of Biological Chemistry.

Discovery of N-{N-[(3-cyanophenyl)sulfonyl]-4(R)-cyclobutylamino-(L)-prolyl}-4-[(3',5'-dichloroisonicotinoyl) amino]-(L)-phenylalanine (MK-0668), an extremely potent and orally active antagonist of very late antigen-4.

P. Davies, M. Maccoss, C. Raab, 2009, Journal of medicinal chemistry.

The Conduct of in Vitro Studies to Address Time-Dependent Inhibition of Drug-Metabolizing Enzymes: A Perspective of the Pharmaceutical Research and Manufacturers of America

Chuang Lu, Heidi J Einolf, Y. Wong, 2009, Drug Metabolism and Disposition.

Pharmacokinetics and Interactions of a Novel Antagonist of Chemokine Receptor 5 (CCR5) with Ritonavir in Rats and Monkeys: Role of CYP3A and P-Glycoprotein

T. Baillie, Sanjeev Kumar, P. Pearson, 2002, Journal of Pharmacology and Experimental Therapeutics.

EVIDENCE FOR THE BIOACTIVATION OF ZOMEPIRAC AND TOLMETIN BY AN OXIDATIVE PATHWAY: IDENTIFICATION OF GLUTATHIONE ADDUCTS IN VITRO IN HUMAN LIVER MICROSOMES AND IN VIVO IN RATS

David C Evans, T. Baillie, M. Braun, 2006, Drug Metabolism and Disposition.

CYTOCHROME P450 3A4 IS THE MAJOR ENZYME INVOLVED IN THE METABOLISM OF THE SUBSTANCE P RECEPTOR ANTAGONIST APREPITANT

P. Lu, R. Sanchez, D. C. Evans, 2004, Drug Metabolism and Disposition.

Characterization of Mice Lacking the Multidrug Resistance Protein Mrp2 (Abcc2)

X. Chu, R. Evers, J. Yabut, 2006, Journal of Pharmacology and Experimental Therapeutics.

Studies on the Mechanism of Simvastatin-Induced Thyroid Hypertrophy and Follicular Cell Adenoma in the Rat

J. Deluca, R. J. Gerson, S. Grossman, 1991, Toxicologic pathology.

IV. Identification of Cytochrome P450 3A Proteins as the Major Enzymes Responsible for the Oxidative Metabolism of Lovastatin in Rat and Human Liver Microsomes

A. Y. Lu, F. Guengerich, P. Thomas, 1991 .

Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation.

T. Baillie, Wei Tang, G. Doss, 2002, Chemical research in toxicology.

Role of Cytochrome P450 Isoforms in the Metabolism of Abamectin and Ivermectin in Rats

J. Woda, Regina W. Wang, B. Halley, 1996 .

Cytochrome P450 in vitro reaction phenotyping: a re-evaluation of approaches used for P450 isoform identification.

A. Y. Lu, Regina W. Wang, J. Lin, 2003, Drug metabolism and disposition: the biological fate of chemicals.

Coimmunoprecipitation of UDP-Glucuronosyltransferase Isoforms and Cytochrome P450 3A4

C. King, Jacqueline J Fremont, Regina W. Wang, 2005, Molecular Pharmacology.

CYTOCHROME P 450 IN VITRO REACTION PHENOTYPING : A RE-EVALUATION OF APPROACHES USED FOR P 450 ISOFORM IDENTIFICATION

Regina W. Wang, LU ANTHONYY.H., J. Lin, 2003 .

Fluorescence characterization of Trp 21 in rat glutathione S‐transferase 1–1: Microconformational changes induced by S‐hexyl glutathione

A. Y. Lu, W. Atkins, D. Newton, 1993, Protein Science.

Characterization of Inducible Nitric-oxide Synthase by Cytochrome P-450 Substrates and Inhibitors

J. Kozarich, S. Grant, Regina W. Wang, 1997, The Journal of Biological Chemistry.

Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes.

A. Y. Lu, F. Guengerich, P. Thomas, 1991, Archives of biochemistry and biophysics.

Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission.

T. Baillie, Wei Tang, D. Dean, 2001, Chemical research in toxicology.

Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent.

A. Y. Lu, W. Atkins, A Y Lu, 2000, Drug metabolism and disposition: the biological fate of chemicals.

FK 506 metabolism in human liver microsomes: investigation of the involvement of cytochrome P450 isozymes other than CYP3A4.

B. Karanam, S. H. Chiu, S. Vincent, 1994, Drug metabolism and disposition: the biological fate of chemicals.

Human cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation and erythromycin N-demethylation. Competition during catalysis.

A. Y. Lu, D. Newton, Regina W. Wang, 1997, Drug metabolism and disposition: the biological fate of chemicals.

Site-directed mutagenesis of glutathione S-transferase YaYa. Important roles of tyrosine 9 and aspartic acid 101 in catalysis.

A. Y. Lu, C. B. Pickett, S. Huskey, 1992, The Journal of biological chemistry.

Effects of the immunosuppressant FK-506 and its analog FK-520 on hepatic and renal cytochrome P450 mixed-function oxidase.

S. Vincent, B. Karanam, S. H. Chiu, 1991, Biochemical pharmacology.

In vitro stimulation of warfarin metabolism by quinidine: increases in the formation of 4'- and 10-hydroxywarfarin.

T. Baillie, Wei Tang, W. Tang, 2001, Drug metabolism and disposition: the biological fate of chemicals.

Validation of (-)-N-3-benzyl-phenobarbital as a selective inhibitor of CYP2C19 in human liver microsomes.

A. D. Rodrigues, T. Baillie, D. Dean, 2004, Drug metabolism and disposition: the biological fate of chemicals.

Utility of recombinant cytochrome p450 enzymes: a drug metabolism perspective.

A. Y. Lu, Wei Tang, Regina W. Wang, 2005, Current drug metabolism.

Assessment of the CYP3A‐Mediated Drug Interaction Potential of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Volunteers

A. Bergman, J. Wagner, R. Krishna, 2009, Journal of clinical pharmacology.